Long-term impact of COVID-19 on haemophilia: a multicenter study in Southwest China Authors: Chun Cao, Shu Chen, Yin Liu, Xiaoyan Tan, Jing Zhu, Jianchuan Deng, Haixia Ma, Tangfei Li, Qunxia Zhang, Xiuni Gan, Xia Wu Published: 2026 ABSTRACT AbstractBackgroundThe coronavirus disease 2019 (COVID-19) pandemic is not yet over as millions of people are still diagnosed with persistent symptoms of COVID-19 (long COVID) worldwide. Despite some advances in haemophilia research, the precise relationship between COVID-19 and haemophilia remains elusive, warranting further investigation.MethodsA total of 254 cases of people with haemophilia (PwH) infected with COVID-19 from Southwest China were enrolled in the present study. Baseline characteristics, clinical manifestations, treatment methods, and vaccination data were collected and analyzed. Patients were followed up for clinical characteristics at 1, 2, 4, and 16 weeks and 6 months after COVID-19. The spontaneous bleeding characteristics, joint functional status (assessed by the Haemophilia Joint Health Score [HJHS] and Haemophilic Early Arthropathy Detection with Ultrasound [HEAD-US]), coagulation factor inhibitors formation, characteristics of long COVID and changes in mental state were analyzed.ResultsThe clinical features of the 254 PwH were analyzed in the study. A significant reduction in spontaneous bleeding frequency was observed in all body regions except the gingiva during COVID-19 (p < 0.05). This pattern of reduced bleeding during infection, followed by an increase post-infection, was observed across the cohort, which included patients with varying severities of haemophilia (severe, n = 167; moderate, n = 59; mild, n = 28). In addition, PwH developed long COVID, characterized by chronic cough (7.87%) and fatigue (5.12%). Six months after COVID-19 infection, approximately 13.39% of PwH showed anxiety and the number of patients with moderate depression and extremely severe depression increased significantly (p < 0.05). During the six-month follow-up, no significant alterations in coagulation factor activity or joint functional status were observed among PwH. A comparison of joint functional status before and after COVID-19 infection revealed no significant difference in the HJHS, with scores of 21.79 ± 15.79 vs 23.81 ± 14.96 (p > 0.05). The HEAD-US Score was 20.33 ± 11.93 vs 20.62 ± 12.61, p > 0.05. In addition, one patient developed coagulation factor Ⅷ inhibitors after COVID-19 infection.ConclusionsThis study indicates that spontaneous bleeding episodes are decreased among PwH during COVID-19 infection, and the infection does not cause deterioration of joint function. In addition, it underscores the necessity of close monitoring of long COVID-related impacts as well as COVID-19-associated mental health conditions in PwH.Clinical trial numberNot applicable.Keywords: Haemophilia, COVID-19, Long COVID, Coagulation factor inhibitors, Mental health Introduction Haemophilia is a congenital bleeding disorder caused by a deficiency of factor Ⅷ (FⅧ), known as haemophilia A, or of factor Ⅸ (FⅨ), known as haemophilia B [1]. The prevalence of haemophilia A is 12.8/100,000 males, and the prevalence of haemophilia B is 2.7/100,000 males [2]. According to statistics, the prevalence of haemophilia in China is 2.73/100,000 individuals, of which haemophilia A accounts for 80–85% [3]. Its main clinical feature is spontaneous or post-traumatic bleeding, with over 80% of bleeds occurring in joints and muscles, leading to haemophilic arthropathy and disabling complications [4–7]. The COVID-19 infection remains a significant public health issue that attracts widespread attention. To date, while extensive research has focused on COVID-19 in the general population, data on its impact on people with haemophilia (PwH) remain scarce. Recent systematic reviews have begun to address this knowledge gap, which have summarized experiences in congenital bleeding disorders, highlighting wide variability in bleeding and thrombotic complications and underscoring the need for well-characterized cohort studies [8]. The coagulation pathophysiology of COVID-19 involves hypercoagulability due to inflammation and endothelial activation, with coagulation disorders reported in up to 50% of severe cases [9, 10]. Therefore, whether this hypercoagulable state can reduce the risk of spontaneous bleeding in PwH remains to be studied. Notably, since repeated joint bleeding may lead to haemophilic arthropathy, changes in the frequency of bleeding may even alter joint functional status in PwH [6]. Additionally, the cytokine storm induced by SARS-CoV-2 might exacerbate haemophilic arthropathy, as inflammatory cytokines (e.g., TNF-α, IFN-γ, IL-1β, IL-6, etc.) drive synovial hyperplasia and bone destruction [11, 12]. Therefore, we speculated that the cytokine storm caused by COVID-19 may contribute to the development of haemophilic arthropathy to some extent. Furthermore, reports of acquired haemophilia following COVID-19 vaccination and infection raise concern about inhibitor formation in PwH [13, 14]. Whether changes in coagulation characteristics and abnormal cytokines in PwH after infection with COVID-19 lead to changes in bleeding frequency, joint function, and inhibitor formation is unclear. Long COVID, caused by SARS-CoV-2, is a debilitating disease that affects millions of people globally and impacts 9–63% of COVID-19 survivors. Its common manifestations include fatigue, cough, and cognitive impairment [15–17]. A recent longitudinal case-control study showed decreased exercise capacity and post-exercise malaise (PEM) in patients with COVID-19 [18]. Further, joint damage can occur in about 20% of PwH receiving prophylactic treatment, even if they are clinically asymptomatic [5]. Therefore, haemophilia complicated by haemophilic arthropathy and PEM poses a substantial challenge to the quality of life and mental health of affected patients. The psychological toll of the COVID-19 pandemic on PwH has been documented, with worries about treatment access and lifestyle disruptions [19]. However, the interplay between long COVID manifestations (particularly post-exertional malaise) and pre-existing haemophilic arthropathy as well as mental health issues among PwH remains insufficiently explored. Given these knowledge gaps, this study aimed to prospectively assess the effects of COVID-19 on bleeding patterns, joint function, inhibitor development, long COVID manifestations, and psychological status in a cohort of PwH in Southwest China, providing evidence to guide clinical management. Subjects and methods Subjects The multicenter study was conducted in Southwest China from December 1, 2022, to August 31, 2023, involving a total of 254 PwH infected with COVID-19. Patients were identified through the haemophilia registration system across five haemophilia treatment centers in four provinces/municipalities, including 118 cases from two centers in Chongqing Municipality, 63 cases from one center in Sichuan Province, 38 cases from one center in Guizhou Province, and 35 cases from one center in Yunnan Province. This study included a cohort of PwH aged 11 and older diagnosed with COVID-19. Baseline assessments were performed in all 254 PwH with COVID-19 infection. The patients were interviewed by questionnaire, survey telephone, or clinic visits. Self-controlled analyses of clinical characteristics were conducted in PwH before, during, and after COVID-19 infection. None of the patients received convalescent plasma or other experimental treatments for COVID-19 and all received standard supportive care according to national guidelines. Study design and data source This case series was designed as a self-controlled study adopting both retrospective and prospective research approaches. Retrospective data on demographics, baseline clinical characteristics, underlying diseases, medication use, COVID-19 vaccination status, and pre-infection clinical status (including bleeding episodes, joint function scores, coagulation factor activity, and inhibitor status) were collected from the haemophilia registration system, medical records and patient diaries. These retrospective data were obtained for the period within one month prior to COVID-19 infection, representing the patients’ status under their usual standard of care immediately preceding the infection. Prospective data were collected following COVID-19 diagnosis. Patients were followed up at predefined intervals including 1, 2, 4, 6 and 16 weeks as well as 6 months after COVID-19 infection. To ensure clarity in temporal comparisons, we defined three distinct periods for analysis of clinical manifestations. (1) Pre-infection period (Before infection): The four-week period immediately preceding COVID-19 diagnosis. Data on clinical manifestations (e.g., bleeding episodes) during this period were retrospectively collected from patient diaries and medical records. (2) During-infection period (During infection): The acute phase of COVID-19 illness, defined as the time from symptom onset or positive test until resolution of acute symptoms. Based on previously reported viral shedding duration for Omicron variants in Chinese populations, the median duration of the acute phase was estimated to be 15–18 days [20]. Accordingly, patients were followed prospectively during this period via weekly telephone interviews or online questionnaires to record bleeding events and symptoms. Bleeding events occurring during this period (wihtin 18 days) were prospectively recorded. (3) Post-infection period (After infection): The four-week period immediately following resolution of acute COVID-19 symptoms. Bleeding events during this period were prospectively recorded. This temporal framework ensures direct comparability of clinical outcomes across the three periods, with the pre-infection period serving as the baseline for each patient. The primary outcomes of the study included the location and frequency of spontaneous bleeding symptoms and the development of long COVID. Secondary outcomes comprised mental state, joint functional status, inhibitor formation, and coagulation factor activity in PwH. The study was conducted in accordance with the Declaration of Helsinki and ethics approval was obtained. Clinical data collection Joint functional status including six index joints (both elbows, knees, and ankles) was assessed using the Haemophilia Joint Health Score (HJHS) version 2.1 and Haemophilic Early Arthropathy Detection with Ultrasound (HEAD-US). HJHS was specifically developed by the International Prevention Research Group of Physiotherapy Specialists to detect early joint changes in haemophilia [21]. The HJHS version 2.1 consists of the assessment of specific features or items of the six-indexed joints, as well as an assessment of overall gait [22]. The HEAD-US score consists of three items with a total score ranging from 0 to 8 points, namely synovial hyperplasia, cartilage destruction and bone destruction [23, 24]. The Philips IU22 colour Doppler ultrasound diagnostic instrument was used for HEAD-US evaluation. The coagulation FⅧ/FⅨ assays, and the coagulation factor inhibitor assays were performed using a Stago instrument and the Bethesda method [25]. For baseline (pre-infection) data, HJHS scores, HEAD-US scores, FⅧ/FⅨ assays, and the Depression Anxiety Stress Scale 21 (DASS-21) test [26] results were obtained from the routine examination records of the haemophilia management center, collected within one month prior to COVID-19 infection. For patients on regular replacement therapy, these assessments were conducted during routine follow-up visits while on their established treatment regimen (either prophylaxis or on-demand therapy), representing their baseline clinical status under standard care. The DASS-21 is routinely administered to all PwH during regular follow-up visits as part of standard psychological care at our participating haemophilia treatment centers. For bleeding episodes, patients were instructed to keep daily diaries to record any bleeding events, including location, date, and treatment administered. Data collection regarding spontaneous bleeding incidents corresponds to three distinct periods. Pre-infection period: Bleeding events occurring in the four weeks before COVID-19 diagnosis were retrospectively extracted from patient diaries and medical records. During-infection period: Bleeding events occurring during acute COVID-19 illness were prospectively recorded via weekly telephone interviews or online questionnaires. Post-infection period: Bleeding events within four weeks after recovery from acute COVID-19 were prospectively recorded through follow-up interviews and patient diaries. Coagulation factor inhibitor assays, belonging to routine check-ups, were carried out in all patients within one month before COVID-19 infection. This pre-infection screening identified patients who were already inhibitor-positive. For patients who were inhibitor-negative at baseline, follow-up inhibitor assays were performed at the 6-month post-infection visit to assess de novo inhibitor development. Acute COVID-19 symptoms and long COVID were assessed at each follow-up time point (1, 2, 4, 6, and 16 weeks post-infection) using a standardized symptom checklist. The stage after the acute phase of COVID-19 includes ongoing symptomatic COVID-19 (4–12 weeks) and post-COVID-19 syndrome (≥12 weeks) [16, 17]. Long COVID is characterized by signs and symptoms that persist or develop after acute COVID-19, which is generally defined as symptoms persisting for 3 months or more after acute COVID-19 [27]. Joint functional status, changes in FⅧ and FⅨ activity and psychological status were assessed using the HJHS scores, HEAD-US scores, FⅧ/FⅨ assays, and DASS-21 at the 6-month post-infection follow-up visit. Statistical analysis Data analysis and drawing are done by SPSS software (version 27.0) and GraphPad Prism (version 9.0). Count data were expressed as n (%) and intergroup comparisons were made using the chi-square (χ2) test, the related sample χ2 test or Fisher’s exact test. Non-normally distributed data were expressed as the median and quartile [M (P25–P75)]. Meanwhile, before-and-after comparisons were made using the related inter-sample Wilcoxon rank-sum test. p < 0.05 indicated statistical significance. Results Demographic and baseline characteristics The study is based on the multicenter system of haemophilia in Southwest China. A total of 254 PwH infected with COVID-19 were followed up. The collected baseline characteristics data included age, height, weight, type of haemophilia, concomitant underlying diseases, factor replacement therapy, aerobic exercise, unhealthy living habits, vaccination, and prophylactic use of antiviral drugs. The median height was 167 (160, 170) cm, and the median weight was 60 (50, 70) kg (Table 1). The geographic distribution of enrolled patients is presented below. A total of 118 (46.46%) from Chongqing Municipality (2 centers), 63 (24.80%) from Sichuan Province (1 center), 38 (14.96%) from Guizhou Province (1 center), and 35 (13.78%) from Yunnan Province (1 center). Among these patients, 78 (30.71%) were aged 11–18 years and 176 (69.29%) were aged ≥ 18 years. There were 219 (86.22%) cases of haemophilia A and 35 cases (13.78%) of haemophilia B. Regarding disease severity, 28 (11.02%) patients presented with mild haemophilia, 59 (23.23%) with moderate haemophilia, and 167 (65.75%) with severe haemophilia. Among them, 62 (24.41%) suffered from underlying diseases (including 5 cases of viral hepatitis, 24 of allergic rhinitis, 13 of hypertension, 13 of diabetes, 1 of coronary heart disease, 2 of cerebrovascular disease, 1 of nephritis, 2 of chronic bronchitis and 5 of hyperlipidemia). Of the participants, 153 cases (60.24%) had hemophilic arthropathy, 152 (59.84%) cases received regular replacement therapy, and 102 (40.16%) cases received on-demand therapy. Weekly exercise duration was less than one hour for 122 (48.03%) cases, two to three hours for 73 (28.74%) cases, three to six hours for 25 (9.84%) cases, six to nine hours for 9 (3.54%) cases and more than nine hours for 25 (9.84%) cases. A total of 184 (72.44%) patients had unhealthy living habits, including 70 who stayed up until 24:00 or later, 13 with unhealthy dietary patterns, 46 smokers, 6 alcohol drinkers and 76 with insufficient physical activity. In terms of COVID-19 vaccination status, 33 (12.99%) patients had no vaccination, 12 (4.72%) received one dose, 95 (37.40%) received two doses, 112 (44.09%) received three doses, and 2 (0.80%) received four doses. In terms of vaccine types, 82 (32.28%) were vaccinated with vaccines from Beijing Institute of Biological Products, 112 (44.09%) with Sinovac vaccines, 13 (5.12%) with Anhui Zhifei Longcom vaccines, 4 (1.57%) with Wuhan Institute of Biological Products vaccines, and 10 (3.95%) with other types of vaccines. Regarding pre-infection drug use, prophylactic or antiviral agents were administered to 18 cases (7.09%) before infection, including thymosin, immunoglobulin, acyclovir, and tenofovir, Huoxiang Zhengqi Water (a traditional Chinese medicine used to strengthen immune function and to promote recovery, containing herbal extracts such as Atractylodes and Magnolia), Yupingfeng powder (a Chinese herbal formula used to strengthen immune function and prevent respiratory infections, containing Astragalus, Atractylodes, and Saposhnikovia). The remaining 236 cases (92.91%) did not receive any prophylactic or antiviral agents before infection. Table 2 summarizes the demographic and baseline characteristics of haemophilia A and haemophilia B patients with COVID-19. Table 1Demographic and baseline characteristics of 254 cases PwH infected of COVID-19Characteristics (n%)Characteristics (n%)AgeTypes of haemophilia <18 years old78 (30.71%)Haemophilia A219 (86.22%) ≥18 years old176 (69.29%)Haemophilia B35 (13.78%)Height (cm)167 (160,170)Weight (kg)60 (50,70)Underlying diseasesTypes of COVID-19 vaccination No192 (75.59%)Unvaccinated33 (12.99%) Viral hepatitis only4 (1.57%)Beijing Biology82 (32.28%) Hypertension only7 (2.76%)Sinovac Biotech112 (44.09%) Allergic rhinitis only23 (9.05%)Anhui Zhifei Biotechnology13 (5.12%) Other disease only7 (2.76%)Wuhan Biology4 (1.57%) Combination of 2 or more21 (8.27%)Other10 (3.95%)Factor replacement therapyUse of prophylaxis and antiviral drugs before infection Regular replacement therapy152 (59.84%)Yes18 (7.09%) On-demand therapy102 (40.16%)No236 (92.91%)Exercise durationUnhealthy living habits Less than 1 hour122 (48.03%)No70 (27.56%) 1–3 hours73 (28.74%)Yes184 (72.44%) 3–6 hours25 (9.84%)Number of unhealthy lifestyle habits 6–9 hours9 (3.55%)0 unhealthy living habit70 (27.56%) More than 9 hours25 (9.84%)1 unhealthy living habit57 (22.44%)Number of COVID-19 vaccinations2 unhealthy living habits51 (20.08%) 033 (12.99%)≥3 unhealthy living habits76 (29.92%) 112 (4.72%)Factor replacement Medications 295 (37.40%)Cryoprecipitate/Plasma1 (0.40%) 3112 (44.09%)Plasma-derived clotting factor concentrates44 (17.32%) 42 (0.80%)Recombinant FⅧ/FⅨ products171 (67.32%)Use two or more/Other38 (14.96%)Height and weight data are expressed as quartile [M (P25–P75)]Unhealthy living habits: staying up late, smoking, drinking alcohol, irregular diet, and insufficient physical activity Demographic and baseline characteristics of 254 cases PwH infected of COVID-19 Height and weight data are expressed as quartile [M (P25–P75)] Unhealthy living habits: staying up late, smoking, drinking alcohol, irregular diet, and insufficient physical activity Table 2General clinical features of 254 cases of PwHCharacteristics (n%)Haemophilia A (n = 219)Haemophilia B (n = 35)Age<18 years old67 (30.59%)11 (31.43%)≥18 years old152 (69.41%)24 (68.57%)The severity of haemophiliaMild23 (10.50%)5 (14.29%)Moderate49 (22.38%)10 (28.57%)Severe147 (67.12%)20 (57.14%)Underlying diseasesYes56 (25.57%)6 (17.14%)No163 (74.43%)29 (82.86%)Factor replacement therapyOn demand therapy84 (38.36%)18 (51.43%)Regular replacement therapy135 (61.64%)17 (48.57%)Haemophilic arthropathyYes133 (60.73%)20 (57.14%)No86 (39.27%)15 (42.86%) General clinical features of 254 cases of PwH Changes in spontaneous bleeding characteristics in PwH with COVID-19 Spontaneous bleeding events were reduced significantly at major bleeding sites, such as joints and muscles, during the period of infection, except for the gingiva. PwH infected with COVID-19 experienced spontaneous bleeding events 264 times one month before infection, 60 times during infection, and 201 times one month after infection. A comparison of factor replacement therapy among PwH across different COVID-19 infection stages was performed. The rates of prophylactic treatment before, during and after infection were 59.84%, 49.21% and 57.09% respectively. There were no significant differences in the proportions of low-dose prophylaxis (11.42% vs. 9.84% vs. 9.84%, p > 0.05), intermediate-dose prophylaxis (33.46% vs. 27.95% vs. 31.89%, p > 0.05) and high-dose prophylaxis (14.96% vs. 11.42% vs. 15.36%, p > 0.05) among the three periods. Significant differences were observed in spontaneous bleeding locations across the three infection stages. The number of joint bleeding episodes was 185, 34 and 114 respectively (p < 0.05), while that of muscle, skin and mucosal bleeding was 52, 5 and 63 respectively (p < 0.05). Joint bleeding events were five times more frequent before COVID-19 infection than during the infection period, and muscle bleeding was ten times more frequent. We also found that joint bleeding and muscle bleeding after infection were respectively three times and twelve times more frequent than those during infection. Thus, the frequency of spontaneous bleeding at different sites in PwH showed different characteristics at different stages of the novel coronavirus epidemic (p < 0.05, Table 3). Additionally, after stratification by haemophilia severity, the number of bleeding episodes declined during COVID-19 infection compared with the preceding month. Specifically, the frequency of bleeding episodes decreased from 210 to 42 in severe cases, from 42 to 12 in moderate cases, and from 12 to 6 in mild cases. Following infection, bleeding episodes increased again across all severity groups (severe: 153 episodes; moderate: 38 episodes; mild: 10 episodes). All available data showed a significant reduction in bleeding events during COVID-19 infection. Table 3Comparison of clinical characteristics before, during and after COVID-19 infection in PwHVariablesBefore infectionDuring infectionAfter infectionχ2P-valueFactor replacement therapy (n = 254)6.5610.363 On demand therapy102 (40.16%)129 (50.79%)109 (42.91%) Low-dose prophylaxis regimens29 (11.42%)25 (9.84%)25 (9.84%) Intermediate-dose prophylaxis regimens85 (33.46%)71 (27.95%)81 (31.89%) High-dose prophylaxis regimens38 (14.96%)29 (11.42%)39 (15.36%)Haemorrhage sites95.372a<0.001 Joint (n = 254)185 (70.07%)34 (56.67%)114 (56.72%)58.018a1<0.001 Muscle or skin mucosa (n = 254)52 (19.70%)5 (8.33%)63 (31.34%)22.779a2<0.001 Gingiva (n = 254)3 (1.14%)16 (26.66%)7 (3.48%) Urinary tract (n = 254)10 (3.79%)1 (1.67%)1 (0.50%) Respiratory tract (n = 254)4 (1.51%)1 (1.67%)1 (0.50%) Intracranial hemorrhage (n = 254)1 (0.38%)0 (0)0 (0) Other parts (n = 254)9 (3.41%)3 (5.00%)15 (7.46%)aFisher’s test1Comparison of before and during COVID-19; 2Comparison of before and after COVID-19 Comparison of clinical characteristics before, during and after COVID-19 infection in PwH aFisher’s test 1Comparison of before and during COVID-19; 2Comparison of before and after COVID-19 Follow-up of joint functional status and coagulation factor inhibitor formation in PwH with COVID-19 The joint functional status, changes in FⅧ and FⅨ activity, and development of inhibitory antibodies to FⅧ/FⅨ in PwH infected with COVID-19 are presented in Table 4. Retrospective statistical analysis was conducted based on follow-up data of 254 PwH, with relevant data collected within one month prior to COVID-19 infection. HJHS scores from 137 patients, HEAD-US scores from 140 patients, FⅧ activity levels from 107 patients and FⅨ activity levels from 16 patients were collected and analyzed. PwH were followed up for 6 months after COVID-19. No significant changes in joint functional status, FⅧ/FⅨ assays, and development of FⅧ/FⅨ inhibitors were found in PwH before and after 6 months of COVID-19 infection (p > 0.05). The joint functional status was presented by HJHS and HEAD-US scores. A comparison of joint functional status before and after COVID-19 infection revealed that the HJHS score was 21.79 ± 15.79 vs 23.81 ± 14.96, p > 0.05. The HEAD-US score was 20.33 ± 11.93 vs 20.62 ± 12.61, p > 0.05. Among the 254 PwH, 16 patients had pre-existing FⅧ inhibitors and 2 had FⅨ inhibitors prior to COVID-19 infection. Notably, one patient developed de novo FⅧ inhibitory antibodies after COVID-19 infection, who had no such inhibitors previously. Table 4Changes in FⅧ and FⅨ activity and joint function in PwH six months after COVID-19 infectionFollow-up contentsBefore COVID-19 infectionAfter COVID-19 infectionZP-valueHJHS score21.79 ± 15.7919 (9,34)23.81 ± 14.9622 (13,33)0.7550.450HEAD-US score20.33 ± 11.9321 (11,29)20.62 ± 12.6122 (9,31)0.4060.684Coagulation FⅧ assay2.26 ± 3.880.48 (0.1,3.0)2.73 ± 2.720.1 (0.1,4.0)1.1000.271Coagulation FⅨ assay1.49 ± 2.480.30 (0.10,1.65)1.81 ± 2.800.25 (0.10,4.68)0.9040.366Quantitative data are expressed as mean±SD or quartile [M (P25–P75)] Changes in FⅧ and FⅨ activity and joint function in PwH six months after COVID-19 infection Quantitative data are expressed as mean±SD or quartile [M (P25–P75)] Acute phase of COVID-19 and long COVID in PwH The clinical characteristics of 254 PwH with COVID-19 infection were followed up for 16 weeks (Table 5). It was found that the main symptoms of COVID-19 in PwH were fever, nasal congestion, cough, expectoration, muscle soreness, decreased appetite, diarrhea, decreased physical strength, taste change, olfactory change, decreased vital capacity, inattention, decreased sexual function, slow reaction, memory loss, etc. For acute COVID-19, the main symptoms in the infection group within one week were fever (68.90%), stuffy nose (29.53%), headache (27.56%), cough (27.56%), runny nose (25.98%), sore throat (25.59%), muscle soreness (24.41%), expectoration (22.44%), decreased appetite (21.26%), fatigue (20.47%), etc. The most common symptoms after 1–2 weeks were cough (18.50%), fatigue (12.99%), expectoration (11.81%), decreased sense of taste (10.24%), and sore throat (9.45%). The main symptoms after 2–4 weeks were cough (8.27%), expectoration (7.09%), fatigue (3.94%), and decreased sense of taste (3.15%). The main symptoms after 4–12 weeks were cough (7.09%), expectoration (4.33%), fatigue (3.54%), sleep quality declines (1.57%), decreased appetite (1.18%), etc. A total of 112 patients (44.1%) presented with post-COVID-19 syndrome after 12 weeks. The main symptoms were cough (7.87%), decreased lung capacity (5.51%), fatigue (5.12%), decreased sleep declines (5.12%), decreased concentration (2.36%), hypomnesia (1.97%), expectoration (1.97%), and decreased sexual function (1.97%) (Table 6, Fig. 1). Taken together, these data suggest that chronic cough and fatigue are the main manifestations of long COVID in PwH. Table 5Symptoms and their duration in PwH after COVID-19 infectionFollow-up periodFeverCoughExpectorationHypoxiaFatigue/Loss of physical strengthDecreased lung capacityInsomniaMuscle sorenessSleep quality declinesHeadacheDecreased sense of taste≤1 week175 (68.90%)70 (27.56%)57 (22.44%)25 (9.84%)52 (20.47%)35 (13.78%)35 (13.78%)62 (24.41%)47 (18.5%)70 (27.56%)50 (19.69%)>1 and ≤2 weeks0 (0)47 (18.50%)30 (11.81%)4 (1.57%)33 (12.99%)15 (5.91%)9 (3.54%)15 (5.91%)13 (5.12%)13 (5.12%)26 (10.24%)>2 and ≤4 weeks0 (0)21 (8.27%)18 (7.09%)6 (2.36%)10 (3.94%)6 (2.36%)5 (1.97%)15 (1.97%)3 (1.18%)5 (1.97%)8 (3.15%)>4 and ≤12 weeks0 (0)18 (7.09%)11 (4.33%)3 (1.18%)9 (3.54%)3 (1.18%)3 (1.18%)1 (0.39%)4 (1.57%)3 (1.18%)3 (1.18%)>12 weeks0 (0)20 (7.87%)5 (1.97%)2 (0.79%)13 (5.12%)14 (5.51%)7 (2.76%)4 (1.57%)13 (5.12%)2 (0.79%)2 (0.79%)Follow-up periodHyposmiaDecreased appetiteDiarrhoeaDecreased sexual functionSlow reactionHypomnesiaDecreased concentrationRunny noseStuffy noseSore throat≤1 week37 (14.57%)54 (21.26%)34 (13.39%)13 (5.12%)31 (12.20%)28 (11.02%)42 (16.54%)66 (25.98%)75 (29.53%)65 (25.59%)>1 and ≤2 weeks20 (7.87%)21 (8.27%)7 (2.76%)8 (3.15%)9 (3.54%)12 (4.72%)8 (3.15%)21 (8.27%)21 (8.27%)24 (9.45%)>2 and ≤4 weeks5 (1.97%)8 (3.15%)0 (0)13 (1.18%)4 (1.57%)4 (1.57%)4 (1.57%)6 (2.36%)8 (3.15%)6 (2.36%)>4 and ≤12 weeks2 (0.79%)3 (1.18%)0 (0)1 (0.39%)2 (0.79%)3 (1.18%)3 (1.18%)3 (1.18%)2 (0.79%)1 (0.39%)>12 weeks5 (1.97%)1 (0.39%)0 (0)5 (1.97%)2 (0.79%)5 (1.97%)6 (2.36%)1 (0.39%)3 (1.18%)2 (0.79%) Symptoms and their duration in PwH after COVID-19 infection Table 6Self-report of mental status and impact on activity of daily living 6 months after COVID-19 infection in PwHPsychological stateYesNoχ2P-valueDelight (n = 254)42 (16.54%)212 (83.46%)757.172<0.001Relaxation (n = 254)81 (31.89%)173 (68.11%)Calm (n = 254)169 (66.54%)85 (33.46%)Anxiety (n = 254)34 (13.39%)220 (86.61%)Depression (n = 254)10 (3.94%)244 (96.06%)Fatigue (n = 254)15 (5.91%)239 (94.09%)Stress (n = 254)19 (7.48%)235 (92.52%)Self-denial (n = 254)1 (0.39%)253 (99.61%)Irritability (n = 254)7 (2.76%)247 (97.24%)Suicidal tendency (n = 254)1 (0.39%)253 (99.61%) Self-report of mental status and impact on activity of daily living 6 months after COVID-19 infection in PwH Symptoms and their duration in PwH after COVID-19 infection Effects of COVID-19 on the mental state of PwH Results showed statistically significant differences in psychological state and activity of daily living after recovery from self-report of 6 months after COVID-19 infection in the 254 cases of PwH (p < 0.05). During self-reported infection, positive emotion reports (delight, relaxation, and calm) were 3.4 times more common than negative emotion reports (anxiety, depression, stress, etc.). In terms of mental state, 169 (66.54%) cases showed calm, whereas 34 (13.39%) cases had anxiety, 10 (3.94%) cases exhibited depression, 19 (7.48%) cases showed stress, and 1 (0.39%) case reported a suicidal tendency (Table 6). Furthermore, we obtained the results of The Depression Anxiety Stress Scale 21 questionnaire before and after COVID-19 infection for 83 patients. DASS-21 data for 83 patients were retrieved from routine assay records at the haemophilia management center, collected within four weeks prior to COVID-19 infection. These patients were subsequently reassessed using the DASS-21 six months post-COVID-19 infection. The score of psychological status before and after infection was 6.12 ± 6.04 vs. 8.19 ± 9.37 for depression, 6.05 ± 5.53 vs. 7.33 ± 6.96 for anxiety, 6.92 ± 6.52 vs. 7.93 ± 7.98 for stress, p > 0.05 (Table 7). A comparative analysis of different severity levels (normal, mild, moderate, severe) revealed no statistically significant difference between anxiety and stress (p > 0.05). However, a notable increase in moderate and extremely severe depression was observed six months following COVID-19 infection p < 0.05 (Table 8). Table 7Mental health scores of PwH at different stages of COVID-19 infection (DASS-21)Characteristic variablesDepressionAnxietyStressBefore COVID-19 infection6.12 ± 6.046.05 ± 5.536.92 ± 6.52After COVID-19 infection8.19 ± 9.377.33 ± 6.967.93 ± 7.98t−1.693−1.309−0.895p-value0.0930.1920.372Quantitative data are expressed as mean±SD Mental health scores of PwH at different stages of COVID-19 infection (DASS-21) Quantitative data are expressed as mean±SD Table 8Comparison of depression, anxiety and stress in PwH at different stages of COVID-19 infectionPeriodDepression(n%)Anxiety(n%)Stress(n%)NormalMildModerateSevereExtremely severeNormalMildModerateSevereExtremely severeNormalMildModerateSevereExtremely severeBefore COVID-19 infection601110205610872725510After COVID-19 infection55416264681766696611χ210.8696.5201.246p-value0.0280.1640.871 Comparison of depression, anxiety and stress in PwH at different stages of COVID-19 infection Discussion Despite the vast knowledge and experience gained since the pandemic, the eradication of COVID-19 caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) remains difficult. The management of haemophilia during COVID-19 is challenging. Meanwhile, long COVID is a crucial complication of COVID-19. To date, data on the effects of SARS-CoV-2 on bleeding patterns, joint function, inhibitor development, and mental health in PwH remain limited [28]. Through the observation and follow-up of PwH with COVID-19, the present study provides data and insights into spontaneous bleeding characteristics, effects on joints functional status and coagulation factor inhibitors, psychological characteristics in PwH after infection and long COVID. Our study found that PwH exhibited a significantly lower rate of spontaneous bleeding, especially in joints and muscles, during COVID-19 infection. We conducted systematic searches in PubMed, Web of Science, Embase and SinoMed to identify studies examining the effects of COVID-19 on bleeding at different body sites in PwH and found that specific clinical features of spontaneous bleeding after COVID-19 infection in PwH have previously been less reported. Although only a few reports have been retrieved, one study by Sait et al. from the Haseena Research Centre contains a description that fits well with our findings [29]. This finding is also consistent with the French study by Volot et al., which reported that during the COVID-19 lockdown, 81% of children and 78% of adults with haemophilia experienced unchanged or decreased bleeding episodes [30]. The authors attributed this reduction to decreased physical activity and improved medication adherence during home quarantine, which aligns with our observation. Moreover, some studies have shown increased levels of procoagulant factors after COVID-19 infection [31–33]. It was previously reported that patients with severe COVID-19 showed coagulation abnormalities, especially von Willebrand Factor, and fibrinogen and elevated D-dimer concentrations [31]. When stratified by haemophilia severity, the reduction in bleeding during COVID-19 infection was consistently observed across all groups. Among severe, moderate, and mild PwH, bleeding episodes decreased by 80, 71, and 50% during infection (from 210 to 42, 42 to 12, and 12 to 6, respectively). Following infection, bleeding increased again across all severity groups, though not returning to pre-infection levels in severe patients (153 vs. 210 episodes). This pattern suggests that the protective effect of COVID-19-associated hypercoagulability may be more pronounced in patients with a high baseline bleeding risk. However, the uniform reduction in spontaneous bleeding frequency across severities also implicates shared factors such as reduced physical activity during lockdowns and stable access to replacement therapy, as all patients continued their prescribed regimens throughout the study period. These findings underscore that the bleeding risk modification during COVID-19 is multifactorial and severity-dependent, warranting individualized monitoring as patients transition back to normal activities. Abnormalities in these pro-coagulation factors may also lead to a reduction in spontaneous bleeding symptoms. The WFH interim guidance on COVID-19-associated coagulopathy emphasized that PwH might present with both bleeding and thrombotic complications, requiring careful management of thromboprophylaxis [34]. Given that haemophilia bleeding frequency is closely related to factor replacement therapy, the abnormality of procoagulant factors alone may not lead to the change in bleeding frequency in PwH. As such, this may be attributed to the standardized comprehensive treatment and nursing care provided for PwH in this region during the COVID-19 period. Of course, other factors may also be involved, such as home isolation and reduced activity during COVID-19 infection, which may also play a role in reducing the frequency of bleeding in PwH. Accordingly, the reduced incidence of spontaneous bleeding in PwH during COVID-19 infection may be related to various factors, such as changes in multiple coagulation promoting factors, standardized factor eplacement therapy, and the reduction in the patient’s physical activity. The systematic review conducted by Dorgalaleh et al. concerning congenital bleeding disorders and COVID-19 reported that among 770 patients with CBDs complicated by COVID-19, bleeding complications were frequently documented in most case series, whereas thrombotic complications were relatively rare. The reported mortality rates ranged from 0% to 5.7%, and hospitalization rates from 0% to 40%, with substantial inter-study variability. Such heterogeneity suggests that well-characterized cohort studies including ours are needed to further supplement current evidence on COVID-19 among this special population [8]. On further analysis, it should be noted that there was no significant change in these parameters in the joint functional status assessment of PwH 6 months after COVID-19 infection compared with the assessment results at the pre-infection level. Specifically, the HJHS score and the HEAD-US score in PwH with COVID-19 showed little change after six months of follow-up. It is known that recurrent joint bleeding in PwH can lead to iron-mediated synovitis and cartilage damage, resulting in joint dysfunction [32]. Therefore, this finding is correlated with the markedly reduced incidence of spontaneous bleeding, especially joint and muscle bleeding, among PwH in our region during COVID-19 infection. Further analysis of the results shows that our Haemophilia Centres have provided adequate support and comprehensive care for PwH during and after COVID-19 to ensure factor replacement therapy for PwH. In conclusion, PwH infected with COVID-19 receive standard prophylactic treatment under standardised management, the frequency of spontaneous bleeding during infection is reduced, and COVID-19 does not cause joint damage in PwH during long-term follow-up. Notably, one patient with haemophilia in our study developed FⅧ inhibitors after COVID-19 infection. Although no direct literature has linked COVID-19 to an elevated risk of coagulation factor inhibitor formation among PwH, several findings have suggested this potential association. COVID-19 vaccine-associated acquired haemophilia has been analyzed and confirmed [13]. A search of the World Health Organization Spontaneous Reporting Database of Adverse Events from Drugs and Vaccines (VigiBase) revealed that COVID-19 vaccine was suspected to cause “Factor Ⅷ inhibition” and “acquired factor Ⅷ deficiency” [13]. A systematic review by Carlson et al. identified 14 cases of acquired haemophilia A following SARS-CoV-2 infection and 28 cases following vaccination, with a significantly more rapid onset observed after vaccination. Their study revealed two shared surface epitopes between the SARS-CoV-2 spike protein and human FⅧ, one of which was specific to the Omicron variant, providing a mechanistic basis for molecular mimicry in inhibitor development [14]. On further analysis, Hirsiger et al. have proposed a mechanism where sequences in the SARS-CoV-2 spike protein overlap with specific immunogenic sequences in FⅧ. This overlap could potentially lead to interactions with endogenous FⅧ-specific autoreactive T-cell clones. This hypothesis suggests that molecular mimicry might play a role in the development of autoantibodies against FⅧ following SARS-CoV-2 infection. A case report by Szabó et al. described a female patient who developed acquired haemophilia A two weeks after SARS-CoV-2 infection, with an inhibitor titer of 2283 BU [35]. In addition, coagulation factor inhibitors in haemophilia have been reported to involve T-helper cells, and it is generally accepted that the anti-FⅧ immune response is predominantly a CD4+ T-cell-dependent humoral immune response with B cell activation [36]. Meanwhile, extensive T-cell apoptosis has been confirmed in COVID-19 patients [11, 37]. There is also evidence that key branches of protective adaptive immunity, such as CD4+ T cells and B cells, are detected in COVID-19 patients after recovery [38]. As such, SARS-CoV-2 could pose a significantly higher risk of developing FⅧ inhibitors after COVID-19 infection. These findings align with our observation of an increased risk of coagulation factor inhibitor formation among PwH following COVID-19 infection. However, whether COVID-19 contributes to coagulation factor inhibitors formation in haemophilia by increasing the risk of CD4+ T cell-dependent humoral immune responses in PwH remains to be explored. Further research with larger sample sizes is needed to confirm and explore this discovery. After follow-up, our data showed that COVID-19 symptoms of PwH in different periods varied with time, and the persistence of symptoms also changed with time. Our study found that 44.1% of the study cohort developed Long-COVID-19 syndrome, with the most common symptoms being cough and fatigue. Although there are few reports on follow-up of PwH with COVID-19, we noted that long COVID in PwH was generally consistent with other populations. Reported long COVID symptoms mainly include fatigue, dyspnea, cognitive impairment/brain fog, discomfort after exercise, memory problems, myalgia/spasticity, cough, sleep disorders, tachycardia/palpitations, and olfactory/taste changes [15]. A recent systematic review estimated the global prevalence of long COVID to be 43%, with the most common symptom being fatigue, followed by memory problems [39]. Similarly, Arjun surveyed 524 COVID-19 patients and found that fatigue (34.9%) was the most common symptom, followed by cough (27.9%) [40]. Similarly, there is also evidence finding fatigue or muscle weakness and difficulty sleeping were the most common symptoms of severe long COVID [41]. Overall, our data suggest that cough and fatigue are the most common long COVID symptoms of PwH. Notably, patients with COVID-19 would have structural changes in skeletal muscle, including local and total metabolic disorders in skeletal muscle, severe exercise-induced myopathy, and tissue infiltration containing amyloid deposits, thereby inducing the deterioration of PEM [18]. Given the impact of chronic fatigue on haemophilic arthropathy, its treatment and the improvement of the quality of life of patients are challenging, and long-term studies of the effects of long COVID on the joint functional status of PwH are warranted. Our findings show that six months after recovering from COVID-19, patients’ scores on the moderate and extremely severe depression assessments increased significantly. Furthermore, this study identified notable differences in psychological state and the impact of COVID-19 on activity of daily living after recovery. Approximately 13.39% of PwH showed anxiety during COVID-19 infection. These findings are consistent with the multicenter study conducted in Germany by von Mackensen et al. [19]. There was evidence of anxiety and fear among PwH worried about the regular supply and production of medicines during COVID-19 [42]. Additionally, PEM after long COVID is more likely to cause depression. Furthermore, the severe pain, joint dysfunction and disability associated with haemophiliac joint disease afflict almost half of PwH, and its psychological impact cannot be ignored [43]. Given this, we recommend that haemophilia management centers adapt and assist patients through digital tools and social networks, including remote monitoring methods such as electronic diaries, handheld devices, and data collection systems to help make decisions, ensure medication supply, track symptoms and patient psychological status, and share disease management and control information with patients and their families [44, 45], ensure that regular factor replacement therapy is carried out normally. Overall, the haemophilia center staff can provide essential support, emotional relief, and foster a close, long-term relationship with PwH during follow-up care. There are some limitations in our study. First, the sample size was relatively small, and the limited sample size may affect the validity of the findings. Secondly, only short-term data were used in the analysis. Therefore, a longer follow-up period is recommended to examine the clinical features of PwH after coronavirus infection. Thirdly, all participants in this study were primarily infected with Omicron variants. Therefore, the findings may not be applicable to other genetic variants of SARS-CoV-2. Additionally, there was limited data on psychological assessments for the participants. Consequently, larger studies are required to investigate the impact of COVID-19 on coagulation factor activity, hemophilic arthropathy, and inhibitors. Conclusion This study demonstrated a reduction in spontaneous bleeding events among PwH during COVID-19 infection, and COVID-19 infection does not lead to deterioration of joint function. In addition, 44.1% of those with haemophilia who contracted COVID-19 developed long COVID, characterized by symptoms such as cough and fatigue. Notably, individuals with haemophilia experienced a significant rise in moderate to severe depression following COVID-19 infection. Furthermore, one patient with haemophilia developed de novo coagulation factor Ⅷ inhibitors following COVID-19 infection. While this observation suggests a potential association, larger studies are required to confirm whether COVID-19 increases the risk of inhibitor development. Therefore, individuals with haemophilia should undergo regular monitoring for long COVID, mental health conditions, and the development of coagulation factor inhibitors. In conclusion, our study provides valuable information and insights into the effects of COVID-19 on PwH.